Follow IQVIA Holdings to never miss an important update.
TD Cowen nudged its price target up from $288 following the company's latest results. This move reflects confidence in the business even as the stock has recently fallen. Other analysts have also adjusted their views, bringing the average target across all firms to about $291. While a price target is just an analyst's estimate of where the stock might trade in a year, the buy rating suggests they believe the company's role in managing drug trials remains a strong bet. The stock currently trades well below these targets, reflecting a gap between analyst expectations and recent market movement.
Source: TD Cowen
Truist Financial raised its price target for the stock from $329 to $346 on Wednesday. This move follows the company's recent earnings report, which showed growing demand for its clinical trial services and a raised forecast for the full year. The new target is well above the current share price of about $266. While several analysts have adjusted their targets recently, the average across the market now sits at roughly $290.
Source: Truist Financial
After IQVIA reported its October results, we updated our fair value and raised our projections for full-year revenue and profit. We have added the quality of the project backlog and the risk of stale contracts to what we track. We also added the profit contributed by minority investments to our analysis of the company's earnings.
IQVIA reported third-quarter earnings of $3.34 per share on revenue of $4.43 billion, both coming in higher than what analysts expected. The company saw growth across its two main businesses: the arm that helps drugmakers run clinical trials and the division that sells healthcare data and analytics.
What matters most for the long term is the $3.2 billion in new bookings this quarter, a 15 percent jump from last year. This adds to a massive backlog of signed work that provides a clear view of future revenue. Because the company is bringing in more cash than expected, management raised its financial targets for the full year. This suggests that pharmaceutical companies are still spending heavily on outsourcing their research, which plays directly into IQVIA's scale advantage.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Stifel Nicolaus raised its price target for IQVIA to 303 dollars, up from its previous target of 276 dollars. This follows a trend of analysts raising their expectations for the stock recently, bringing the average target across all firms to about 285 dollars. While the firm did not change its overall rating, the higher target suggests more confidence in the company's ability to grow its clinical research and data business. The stock currently trades around 270 dollars.
Source: Stifel Nicolaus
Management consistently clears the bar with small, steady beats every quarter, showing they have a tight grip on forecasting and a business that runs like clockwork.
| Expectation | |
|---|---|
| EPS | $3.60 |
| Revenue | $4.53B |
Follow IQVIA Holdings to get the latest and most important updates.
Follow IQV